H.C. Wainwright Remains Bullish on Corcept Therapeutics Incorporated (CORT)
Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the most profitable biotech stocks to invest in now. On July 14, H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Corcept Therapeutics Incorporated (NASDAQ:CORT) and set a price target of $145.00.
A biologist in a lab coat studying a culture of cells to find a cure for metabolic disorders.
Corcept Therapeutics Incorporated (NASDAQ:CORT) reported $157.2 million in revenue in fiscal Q1 2025 compared to $146.8 million in the same quarter last year.
Net income per common share (diluted) for the quarter was $0.17, compared to $0.25 in Q1 2024. The company also reiterated its 2025 revenue guidance of $900 million to $950 million.
Corcept Therapeutics Incorporated (NASDAQ:CORT) is a biopharmaceutical company that develops and commercializes therapies that adjust the effects of cortisol, a hormone that regulates various bodily functions.
The company’s flagship product, Korlym, is FDA-approved for treating Cushing’s syndrome, a disorder caused by excessive cortisol production.
While we acknowledge the potential of CORT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.